Aptus Pharma IPO Listing at 15.42% Premium at ₹80.80 Per Share
Wed Oct 01 2025
Click and Sign Up to Get Latest Updates on Aptus Pharma Limited
Aptus Pharma IPO Listing: The Aptus Pharma IPO was subscribed 22.27 times as of its closing. In this subscription, qualified institutional buyers (QIBs) received 1.24 times the allocation, and non-institutional investors (NIIs) received 28.75 times the allocation. The retail quota of the issue was subscribed to 33.33%. Before delving deeper into the topic, go through the details of the Aptus Pharma IPO.
Aptus Pharma IPO Listing
On the BSE (National Stock Exchange), shares are listed at ₹80.80 per share, representing a 15.42% premium over the issue price of ₹70 per share.
Aptus Pharma IPO Details
It is a bookbuilding IPO of ₹13.02 crore, comprising a fresh issue of 0.19 crore shares. The problem will be listed on BSE and SME on its tentative listing date, 30th September 2025.
The Aptus Pharma IPO date is fixed between 23rd September 2025 and 25th September 2025. The face value of Aptus Pharma IPO shares stands at ₹10 per share, and the IPO price is set at ₹65.00 to ₹70.00 per share.
| IPO Open Date | 23rd September 2025 |
| IPO Close Date | 25th September 2025 |
| IPO Allotment Date | 26th September 2025 |
| Refund Initiation | 29th September 2025 |
| Issue Size | 18,60,000 shares(aggregating up to ₹13.02 Cr) |
| Face Value | ₹10 per share |
| Lot Size | 2,000 shares |
| Issue Price Band | ₹65.00 to ₹70.00 per share |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE & SME |
| Listing Date | 30th September 2025 |
About Aptus Pharma Limited
Aptus Pharma Ltd is engaged in the business of marketing, and distribution of finished pharmaceutical formulations The company manufactures and distributors of a broad range of pharmaceutical formulations covering multiple therapeutic areas: antacids & PPIs, pain management, anti-inflammatories, antibiotics, cardiology & antidiabetics, neuropsychiatry, dental, injectable parenterals, syrups, nutraceuticals, sachets, and more.
Aptus Pharma Limited Financials
The company’s financial analysis is crucial before applying for the Aptus Pharma IPO. Refer to the table to learn about Aptus Pharma Limited’s financials.
| Year Ended | 31st March 2025 (in cr.) | 31st March 2024 (in cr.) | 31st March 2023 (in cr.) |
| Assets | 21.92 | 10.03 | 6.22 |
| Revenue | 24.64 | 17.88 | 13.90 |
| Profit After Tax | 3.10 | 0.80 | 0.19 |
| EBITDA | 4.76 | 1.49 | 0.57 |
| Net Worth | 6.97 | 1.77 | 0.97 |
| Reserve and surplus | 1.97 | 1.47 | 0.67 |
| Total Borrowing | 10.36 | 5.31 | 2.21 |
Explanation
Aptus Pharma Limited’s revenue increased by 38% from ₹17.88 crores in March 2024 to ₹24.64 crores in March 2025. Moreover, the company’s PAT rose by 288% from ₹0.80 crores to ₹3.10 crores.
Download the Univest iOS App or Univest Android App to get daily stock recommendations and insightful research pieces!
Recent Articles
Top 10 Penny Stocks in India | Penny Stocks to Buy in 2025
Best Stocks to Buy Today: Explore Best Stocks With Expected Trends
Milky Mist Dairy Foods IPO Details: Everything You Should Know about
Karbonsteel Engineering IPO GMP & Review: Should You Apply or Avoid?
Taurian MPS IPO GMP & Review: Should You Apply or Avoid?
Shringar House of Mangalsutra IPO GMP & Review: Apply or Avoid?
Dev Accelerator IPO GMP & Review: Apply or Avoid?
